For patients whose metastatic lung cancers have exhausted standard treatment options, new targeted therapies offer renewed hope for meaningful tumor control. This matters particularly for the subset of non-small cell lung cancer patients whose tumors overexpress HER2 protein, a population historically underserved by precision medicine approaches.
The DESTINY-Lung03 trial evaluated trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate that delivers cytotoxic payload directly to HER2-expressing cancer cells. Among 36 patients receiving T-DXd monotherapy at 5.4 mg/kg, investigators documented a 44.4% confirmed response rate. The combination arms testing T-DXd with durvalumab immunotherapy and platinum chemotherapy showed promise but encountered significant toxicity challenges, including grade 4-5 thrombocytopenia and febrile neutropenia that led to treatment discontinuation.
This response rate represents substantial activity in a heavily pretreated population where conventional options typically yield single-digit response rates. The antibody-drug conjugate approach leverages HER2 targeting to concentrate chemotherapy within tumor cells while theoretically sparing healthy tissue. However, the severe hematologic toxicity observed with combination regimens suggests that maximizing efficacy while maintaining tolerability remains a delicate balance.
These findings position T-DXd monotherapy as a viable option for HER2-overexpressing lung cancer, joining the growing arsenal of precision therapies that target specific molecular drivers. The challenge ahead lies in identifying optimal sequencing with other targeted agents and determining whether combination approaches can be refined to improve the therapeutic index without compromising the meaningful single-agent activity demonstrated here.